UTHR stock forecast
Our latest prediction for United Therapeutics Corp.'s stock price was made on the April 9, 2018 when the stock price was at 110.38$.
In the short term (2weeks), UTHR's stock price should outperform the market by 0.12%. During that period the price should oscillate between -4.97% and +5.83%.
In the medium term (3months), UTHR's stock price should outperform the market by 0.79%. During that period the price should oscillate between -11.56% and +14.98%.Get email alerts
About United Therapeutics Corp.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
At the moment the company generates 1711M USD in revenues.
On its last earning announcement, the company reported a profit of 12.39$ per share.
The book value per share is 59.33$
Three months stock forecastApril 9, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|